Skip to main content
. 2018 Jun 22;9(48):28935–28950. doi: 10.18632/oncotarget.25649

Figure 2. 64Cu-ipRIT in an early-phase peritoneal dissemination model with HCT116-RFP cells.

Figure 2

(A) Representative images of mice treated with 64Cu-ipRIT against early-phase peritoneal dissemination of HCT116-RFP cells (saline control, 64Cu-PCTA-cetuximab, 64Cu-PCTA-trastuzumab, cetuximab without 64Cu, and trastuzumab without 64Cu groups). Tumor growth was observed by in vivo fluorescence imaging. (B) Survival curves (n = 6). *P < 0.05 vs. saline control (log-rank test)